ORAL RITLECITINIB AND BREPOCITINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS: CHRONIC THERAPY DATA FROM THE VIBRATO UMBRELLA STUDY
William Sandborn 1
Silvio Danese 2
Jaroslaw Leszczyszyn 3
Jacek Romatowski 4
Engin Altintas 5
Elena Peeva 6
Michael Vincent 6
Padmalatha Reddy 6
Christopher Banfield 6
Anindita Banerjee 6
Jeremy Gale 6
Kenneth Hung 6
1 University of California San Diego, San Diego, United States
2 IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
3 Melita Medical Center, Wroclaw, Poland
4 Provincial Complex Hospital, Bialystok, Poland
5 Mersin University, Mersin, Turkey
6 Pfizer Inc., Cambridge, United States
Topic
IBD, Nurses, Primary Care
Conference
UEG Week Vienna 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]